Transcode TherapeuticsRNAZ
13F holders, Q1 2026 (March 31)8holders +2
2new positions
2sold out
$8.61avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Transcode Therapeutics Inc. (RNAZ) in their 13F filings, up 2 from Q4 2025. 2 opened new positions and 2 sold out. The largest holders were Geode Capital Management, LLC ($110K), UBS Group AG ($71K) and Vanguard Capital Management LLC ($56K).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $110K |
| Exits | 2 | $75 |
All 13F filers, Q4 2025 → Q1 2026: 18,128 shares bought and 670 shares sold, net +17,458 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Geode Capital Management, LLC | 0.00% | New | 12,740 | $110K |
| UBS Group AG | 0.00% | Add +179.9% | 8,295 | $71K |
| Vanguard Capital Management LLC | 0.00% | — | 6,545 | $56K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 2,982 | $26K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -74.3% | 228 | $2K |
| Wells Fargo & Company | 0.00% | New | 55 | $474 |
| SBI Securities Co., Ltd. | 0.00% | Add +20.0% | 12 | $103 |
| Royal Bank of Canada | 0.00% | No change | 8 | $0 |
"% of holder's portfolio" is RNAZ's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.